Last week bard1 or ASX:BD1 revealed results from its trials using its patent SubB2m technology showing 100% specificity and sensitivity for detection of all stages of ovarian cancer. Early this week they revealed data showing the same SubB2m technology can also detect Breast cancer at all stages with 100% specificity and over 95% sensitivity.
SubB2M is a protein that binds specifically to a sugar molecule called Neu5Gc which is present on a range of cancers. In humans, Neu5Gc is only found on human tumour cells and tumour-associated molecules, potentially making Neu5Gc a highly specific pan-cancer biomarker. BARD1 holds the exclusive worldwide license for the use of SubB2M to detect any cancer.
Researchers from the University of Adelaide and Griffith University have engineered the SubB2M protein to have exquisite specificity for binding to Neu5Gc, and have proven its ability to detect Neu5Gc in the bloodstream of cancer patients.
It had got an initial hype a couple days ago and obviously they have a while to go before producing a product that they can distribute and sell but it is good news in the fight against cancer.
Submitted February 17, 2021 at 07:05PM by kyro2000 https://ift.tt/3pzk8J4
